Angewandte Chemie International Edition · 2020 · 80 citations · 41 references
MedicineMedicinal ChemistryOncologyCancer PharmacologyChemotherapyMolecular OncologyEnzyme InhibitionTargeting LigandsTopoisomerase InhibitorsAnti-apoptotic AgentsCatalytic Topoisomerase InhibitionDna Topoisomerase I InhibitionDual-target InhibitorsPlatinum CompoundsTopoisomerase I InhibitorsTopoisomerase Ii Inhibitors
Inducing necroptosis in cancer cells is an effective approach to circumvent drug-resistance. Metal-based triggers have, however, rarely been reported. Ruthenium(II) complexes containing 1,1-(pyrazin-2-yl)pyreno[4,5-e][1,2,4]triazine were developed with a series of different ancillary ligands (Ru1-7). The combination of the main ligand with bipyridyl and phenylpyridyl ligands endows Ru7 with superior nucleus-targeting properties. As a rare dual catalytic inhibitor, Ru7 effectively inhibits the endogenous activities of topoisomerase (topo) I and II and kills cancer cells by necroptosis. The cell signaling pathway from topo inhibition to necroptosis was elucidated. Furthermore, Ru7 displays significant antitumor activity against drug-resistant cancer cells in vivo. To the best of our knowledge, Ru7 is the first Ru-based necroptosis-inducing chemotherapeutic agent.
41
Jean-Pierre Gillet, Anna Maria Calcagno, Sudhir Varma et al. · Proceedings of the National Academy of Sciences · 2011 · 474 citations · Full text
Medicine, Cancer Biology, Oncology +16
Shikonin circumvents cancer drug resistance by induction of a necroptotic death
Weidong Han, Ling Li, Shuang Qiu et al. · Molecular Cancer Therapeutics · 2007 · 362 citations
Ana Rilak Simović, Romana Masnikosa, I. Bratsos et al. · Coordination Chemistry Reviews · 2019 · 202 citations · Full text